Showing results (121-130 of 3,013) with videos related to
Sort By:
Pageof 302
Cardiovascular Drugs and Therapy|February 23, 2011
Clinical Trials Update AHA Congress 2010John D Horowitz, Robert S Rosenson, John J V McMurray, et al.Cardiovascular Drugs and Therapy|August 1, 1990
Flecainide acetate dose-concentration relationship in cardiac arrhythmias: influence of heart failure and amiodaroneJ F Leclercq, I Denjoy, F Mentré, et al.Cardiovascular Drugs and Therapy|June 1, 1990
Clinical aspects of trial design: what can we expect from the cardiac arrhythmia suppression trial?J T BiggerCardiovascular Drugs and Therapy|June 1, 1990
Class IC drugs: propafenone and flecainideP Puech, J P GagnolCardiovascular Drugs and Therapy|June 1, 1990
Efficacy of encainide in supraventricular arrhythmiasP E PoolCardiovascular Drugs and Therapy|April 1, 1990
Hemodynamic and coronary vasodilative action of two nitroglycerin oral spray formulationsR E Gansser, A Schneeweiss, M Weiss, et al.Cardiovascular Drugs and Therapy|April 10, 2010
Additive effect of TAK-491, a new angiotensin receptor blocker, and pioglitazone, in reducing myocardial infarct sizeYumei Ye, Kyle T Keyes, Chong F Zhang, et al.Cardiovascular Drugs and Therapy|February 1, 1991
Electrophysiologic effects of FPL 13210 on canine Purkinje fiber action potential duration and Vmax comparison to disopyramideT K Knilans, A Varró, P P Nánási, et al.Cardiovascular Drugs and Therapy|April 13, 2010
A multicenter, eight-week treatment, single-step titration, open-label study assessing the percentage of Korean dyslipidemic patients achieving LDL cholesterol target with atorvastatin starting doses of 10 mg, 20 mg and 40 mgCheol Whan Lee, Sang-Hong Baek, Taek-Jong Hong, et al.Cardiovascular Drugs and Therapy|June 29, 2010
Neonatal exendin-4 leads to protection from reperfusion injury and reduced rates of oxidative phosphorylation in the adult rat heartSuzanne B Brown, Joseph R Libonati, Mary A Selak, et al.Pageof 302